

# Circulating FGF18 is decreased in pleural mesothelioma but not correlated with disease prognosis

---

Mosleh, Berta; Schelch, Karin; Mohr, Thomas; Klikovits, Thomas; Wagner, Christina; Ratzinger, Lukas; Dong, Yawen; Sinn, Katharina; Ries, Alexander; Berger, Walter; ...

Source / Izvornik: **Thoracic Cancer, 2023, 14, 2177 - 2186**

Journal article, Published version

Rad u časopisu, Objavljena verzija rada (izdavačev PDF)

<https://doi.org/10.1111/1759-7714.15004>

Permanent link / Trajna poveznica: <https://um.nsk.hr/um:nbn:hr:105:778143>

Rights / Prava: [Attribution 4.0 International](#) / [Imenovanje 4.0 međunarodna](#)

Download date / Datum preuzimanja: **2024-05-15**






Repository / Repozitorij:

[Dr Med - University of Zagreb School of Medicine Digital Repository](#)



# Circulating FGF18 is decreased in pleural mesothelioma but not correlated with disease prognosis

Berta Mosleh<sup>1</sup> | Karin Schelch<sup>1,2</sup> | Thomas Mohr<sup>2</sup> | Thomas Klikovits<sup>1</sup> |  
Christina Wagner<sup>2</sup> | Lukas Ratzinger<sup>2</sup> | Yawen Dong<sup>1</sup> | Katharina Sinn<sup>1</sup> |  
Alexander Ries<sup>2</sup> | Walter Berger<sup>2</sup> | Bettina Grasl-Kraupp<sup>2</sup> | Konrad Hoetzenecker<sup>1</sup> |  
Viktoria Laszlo<sup>1</sup> | Balazs Dome<sup>1,3,4</sup>  | Balazs Hegedus<sup>1</sup>  | Marko Jakopovic<sup>5</sup> |  
Mir Alireza Hoda<sup>1</sup> | Michael Grusch<sup>2</sup> 

<sup>1</sup>Department of Thoracic Surgery, Medical University of Vienna, Vienna, Austria

<sup>2</sup>Center for Cancer Research, Medical University of Vienna, Vienna, Austria

<sup>3</sup>National Koranyi Institute of Pulmonology, Budapest, Hungary

<sup>4</sup>Department of Thoracic Surgery, National Institute of Oncology-Semmelweis University, Budapest, Hungary

<sup>5</sup>Department for Respiratory Diseases Jordanovac, University of Zagreb School of Medicine, University Hospital Centre Zagreb, Zagreb, Croatia

## Correspondence

Michael Grusch, Center for Cancer Research, Medical University of Vienna, Borschkegasse 8a, A-1090 Vienna, Austria.

Email: [michael.grusch@meduniwien.ac.at](mailto:michael.grusch@meduniwien.ac.at)

## Funding information

Austrian Science Fund, Grant/Award Numbers: FWF I3522, FWF I3977, FWF I4677; City of Vienna Fund for Innovative Interdisciplinary Cancer Research, Grant/Award Number: 21132

## Abstract

**Background:** Pleural mesothelioma (PM) is a relatively rare malignancy with limited treatment options and dismal prognosis. We have previously found elevated FGF18 expression in PM tissue specimens compared with normal mesothelium. The objective of the current study was to further explore the role of FGF18 in PM and evaluate its suitability as a circulating biomarker.

**Methods:** FGF18 mRNA expression was analyzed by real-time PCR in cell lines and in silico in datasets from the Cancer Genome Atlas (TCGA). Cell lines overexpressing FGF18 were generated by retroviral transduction and cell behavior was investigated by clonogenic growth and transwell assays. Plasma was collected from 40 PM patients, six patients with pleural fibrosis, and 40 healthy controls. Circulating FGF18 was measured by ELISA and correlated to clinicopathological parameters.

**Results:** FGF18 showed high mRNA expression in PM and PM-derived cell lines. PM patients with high FGF18 mRNA expression showed a trend toward longer overall survival (OS) in the TCGA dataset. In PM cells with low endogenous FGF18 expression, forced overexpression of FGF18 resulted in reduced growth but increased migration. Surprisingly, despite the high FGF18 mRNA levels observed in PM, circulating FGF18 protein was significantly lower in PM patients and patients with pleural fibrosis than in healthy controls. No significant association of circulating FGF18 with OS or other disease parameters of PM patients was observed.

**Conclusions:** FGF18 is not a prognostic biomarker in PM. Its role in PM tumor biology and the clinical significance of decreased plasma FGF18 in PM patients warrant further investigation.

## KEYWORDS

biomarker, FGF18, fibroblast growth factor 18, pleural mesothelioma

## INTRODUCTION

Pleural mesothelioma (PM) is a relatively rare malignancy with poor prognosis, limited therapeutic options, and a lack of reliable biomarkers to aid in diagnosis and patient stratification.<sup>1</sup> Despite the demonstrated usefulness of

mesothelin and calretinin as blood-based biomarkers,<sup>2,3</sup> both the diagnosis and establishment of prognosis of PM are often challenging tasks. Accordingly, novel biomarkers are important to facilitate an earlier and more accurate diagnosis, as well as to provide prognostic information for clinicians.

This is an open access article under the terms of the [Creative Commons Attribution](https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2023 The Authors. *Thoracic Cancer* published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.

FGF18 is a secreted glycoprotein and belongs to the fibroblast growth factor (FGF)/fibroblast growth factor receptor (FGFR) family that consists of 18 ligands and 4 transmembrane receptor tyrosine kinases.<sup>4</sup> Various FGFR family members have been shown to play important roles in an increasing number of malignant diseases.<sup>5</sup> Our group<sup>6–8</sup> and others<sup>9–12</sup> have shown the importance of the FGF/FGFR signaling axis in PM in recent years. In particular, FGF2 has been reported to be overexpressed in PM cell lines and tissues and to enhance cell proliferation and epithelial to mesenchymal transition (EMT).<sup>6,7,11</sup> Moreover, high FGF2 levels in the blood and in pleural effusions have been correlated with tumor aggressiveness and worse prognosis.<sup>9,12</sup> FGF18, like FGF2, is overexpressed in PM tissue specimens compared with normal pleura and has shown higher gene expression levels in PM cell lines than in normal mesothelial cells.<sup>6</sup> However, in contrast to FGF2, which binds all FGFR isoforms, FGF18 has shown preferential binding to FGFR3.<sup>13</sup> FGFR3 has shown a more restricted expression pattern in PM patients compared with FGFR1 and FGFR2 in a previous immunohistochemistry study and was significantly associated with poorer overall survival (OS).<sup>8</sup>

Physiologically, FGF18 plays a crucial role in the development of skeleton, cartilage, lung, and brain.<sup>14–16</sup> With regard to malignant diseases, FGF18 has been shown to be overexpressed in several cancer types including hepatocellular, ovarian, and colorectal cancers.<sup>17–20</sup> Moreover, it has been shown to contribute to enhanced cell proliferation, migration, invasion, neoangiogenesis, and drug tolerance in a number of normal and malignant cell types.<sup>19,21–23</sup> In ovarian cancer, FGF18 was identified as a blood-based biomarker by secretome analysis and enhanced FGF18 levels were confirmed by ELISA in the blood from ovarian cancer patients compared with a control group.<sup>24</sup>

In the current study, we further explored the role of FGF18 in pleural mesothelioma and evaluated its suitability as a blood-based biomarker.

## METHODS

### Cell lines

Cells were cultured in growth medium with 10% fetal bovine serum (FBS) at 37°C in a humidified atmosphere with 5% CO<sub>2</sub> and regularly checked for mycoplasma contamination. Cell line names, cancer type and source for each cell line are listed in Table S1. Cell line authentication was done by array comparative genomic hybridization and short tandem repeat (STR) analysis as described.<sup>25</sup>

### Determination of FGF18 gene expression by quantitative real-time PCR (qRT-PCR)

Cells were grown in flasks to about 80% confluence. Total RNA was extracted with the innuPREP RNA mini kit

(Analytik Jena) according to the manufacturer's instructions. RNA was reverse transcribed with reverse transcriptase (M-MLV, Thermo Fisher Scientific). The resulting cDNAs were used as templates for qRT-PCR analysis with Taqman assays for FGF18 (Hs00826077m1) and GAPDH (Hs99999905m1) both from Thermo Fisher Scientific. Relative gene expression levels were calculated as  $2^{-\Delta C_t} \times 10^4$  of FGF18 normalized to the housekeeping gene GAPDH as previously published.<sup>6</sup>

### Extraction of FGF18 gene expression and survival data from the TCGA mesothelioma dataset

RNASeq expression data for FGF18 as well as clinical data were downloaded into R using the TCGAbiolinks package [<https://doi.org/10.1371/journal.pcbi.1006701>].

### Generation of FGF18 overexpressing cell lines

A retroviral expression construct for FGF18 was generated by amplifying the full open reading frame of FGF18 with a proofreading polymerase (Q5, New England Biolabs) and primers FGF18-for: 5'-TTTTTAATTAACGATGTATTCA GCGCCCTC-3' and FGF18-rev: 5'-TTTTTAATTAACCT AGGCAGGGTGTGTG-3' from cDNA of the PM cell line M38K and ligating the amplicon into the retroviral expression vector pQCXIP (Takara Bio). After sequence verification, viral particles were generated by transient co-transfection of the FGF18 expression construct or the empty pQCXIP vector (as vector control) with the two helper plasmids VSV-G and pgag-pol-gpt into HEK293 cells. Supernatants containing viral particles were used for target cell transduction and cells with stable integration of the FGF18 construct were selected with puromycin (0.8 µg/mL) as published.<sup>26</sup> Overexpression of FGF18 was confirmed by qRT-PCR as outlined above.

### Clonogenic growth assays

Cells were seeded at low density (10<sup>3</sup> per well) into 24-well plates and allowed to grow for up to 14 days until cell clones had formed. Then cells were washed with PBS, fixed with methanol-glacial acetic acid (3:1) for 20 min and again washed with PBS. Afterward cells were stained with crystal violet (10% in ethanol, 1:1000 in PBS) for 1–3 h. To remove the excessive crystal violet, the plates were washed and air-dried overnight. Images of the stained colonies were taken with a Nikon D90 camera, and afterward the cells were destained with 2% SDS for about 3 h. The solution was transferred into microtiter 96-well plates and the absorption at 562 nm was photometrically measured with a SynergyHT plate reader.

## Migration assays

For analyzing cell migration, transwell assays using BD Falcon 8  $\mu\text{m}$  pore size cell culture inserts in a 24-well format were performed. Cells ( $10^4$  per well) were seeded into transwell chambers and allowed to transmigrate for 24 h. Cells that had transmigrated to the lower surface of the chamber were fixed with cold methanol for 20 min, whereas cells that remained on the upper surface were removed using a cotton stick. Afterward, cells were washed, stained with crystal violet, washed again, destained with 2% SDS and absorbance of the solution was measured at 562 nm as outlined above for the clonogenic growth assay.

## Patients

Plasma samples were collected from 40 patients with histologically confirmed PM at the time of diagnosis and/or before surgical resection. None of the patients had received talc pleurodesis before blood collection. Twenty-nine samples were obtained at the Department of Thoracic Surgery, Medical University of Vienna. Eleven samples were collected at the University of Zagreb, School of Medicine, Department for Respiratory Diseases Jordanovac, University Hospital Center Zagreb, Croatia. Samples from 40 healthy individuals and six patients with benign pleural diseases (2 with asbestos-induced diffuse pleural fibrosis, 3 with inflammation-induced pleural fibrosis of unknown origin, and 1 with hyaluronan-induced pleural fibrosis) served as controls. In all analyzed patients, PM diagnosis was histologically proven during clinical routine work-up. The latest version of the TNM IMIG/IASLC staging system<sup>27</sup> was used for clinical and pathological tumor staging. Clinical data and plasma samples were collected prospectively for all cases according to the corresponding local ethic committees of each center.

## Determination of circulating levels of FGF18

Circulating FGF18 was measured in plasma samples with the FGF18 ELISA kit from USCN (USC-SEC907HU). Sample preparation, generation of standard curves, and measurement of samples in duplicates were done following the manufacturer's instructions.

## Statistical analysis


Categorical data are displayed as counts and percentages and metric data are given as median and interquartile range (IQR), or, in case of survival, as median and corresponding 95% confidence interval (CI) if not otherwise indicated. In the plasma sample test cohort as well as in the TCGA dataset, patients were divided into high and low FGF18 level groups by the median value (112.3 pg/mL) of protein and relative

gene expression (320.9), respectively, as in previous studies.<sup>28,29</sup> To compare groups, Mann–Whitney U tests, Kruskal–Wallis or Chi-square-tests were performed as appropriate. The correlation of metric data was analyzed by Pearson's correlation coefficient. Overall survival was defined as time between diagnosis and death or last follow-up date. Survival was estimated by the Kaplan–Meier method and log rank test. Breslow test was used to compare the group differences as appropriate. Univariate and multivariate Cox regression models were used to evaluate the effect of other potential influencing factors, such as age, sex, histology, stage, and treatment. For experiments involving cell lines, data were obtained from  $n \geq 3$  replicates and unpaired  $t$ -tests were used for comparisons of two groups. Differences were considered statistically significant for  $p$  values  $<0.05$ . Statistical analyses were performed using the SPSS 28.0 software system (SPSS Inc.) and plots were generated with GraphPad Prism 8.

## RESULTS

### Comparison of FGF18 gene expression in pleural mesothelioma and other cancer types and correlation with survival of mesothelioma patients

Our previous work showing higher FGF18 expression in PM cell lines compared with mesothelial cells<sup>6</sup> prompted us to compare FGF18 gene expression in PM cell lines with cell lines from other malignancies including lung cancer, colon cancer, and melanoma. Indeed, pleural mesothelioma cells showed on average the highest gene expression levels of the whole cell line panel (Figure 1a, Table S1). These data are in line with the gene expression data from the TCGA consortium (<https://www.cancer.gov/about-nci/organization/ccg/research/structural-genomics/tcga>), where pleural mesothelioma tissue



**FIGURE 1** FGF18 gene expression levels are high in pleural mesothelioma (PM) cell lines and tend to be higher in mesothelioma patients with longer overall survival. (a) FGF18 gene expression was analyzed by qRT-PCR and normalized to the housekeeping gene GAPDH in cell lines from malignant PM, lung cancer, melanoma, colorectal cancer (CRC), leukemia and hepatocellular carcinoma (HCC). Each dot represents one cell line; medians for each cancer type are indicated by horizontal lines. (b) Data were extracted from the TCGA dataset ( $n = 85$ ). Kaplan–Meier survival analysis was performed for patients with high and low FGF18 gene expression with the median FGF18 expression level used as a cutoff.

showed the second highest FGF18 expression after ovarian cancer across 32 cancer types when analyzed on the UALCAN portal (Figure S1).<sup>30</sup> Among the eight PM cell lines, no difference between those derived from epithelioid PM ( $n = 5$ ) and those from biphasic PM ( $n = 3$ ) and no difference between BAP1<sup>+</sup> ( $n = 6$ ) and BAP1<sup>-</sup> ( $n = 2$ ) cell lines were apparent (Figure S2).

The high FGF18 mRNA expression in PM cell lines as compared with cell lines from other cancer types suggested a potentially important role of FGF18 in PM, and therefore we next retrieved FGF18 gene expression data from the TCGA dataset of PM patients ( $n = 85$ ). A comparison of FGF18 mRNA expression with patient survival revealed a trend towards longer OS in patients with high FGF18 (Figure 1b) which was, however, not statistically significant (median survival of 17.867 vs. 20.267 months in the FGF low vs. FGF18 high group, HR 1.397, 95% CI: 0.867–2.250,  $p = 0.168$ ).


### Impact of FGF18 on pleural mesothelioma cell growth and migration

Since the gene expression data suggested that FGF18 is overexpressed in PM but could be connected to longer OS, we next explored potential effects of FGF18 overexpression on PM cells. For that purpose, we selected M38K and SPC212, 2 PM cell lines with low to moderate endogenous FGF18 expression (Table S1), to generate sublines stably overexpressing FGF18 (M38K<sup>FGF18</sup>, SPC212<sup>FGF18</sup>) and the respective empty vector controls (M38K<sup>VC</sup>, SPC212<sup>VC</sup>). Parental M38K had a higher endogenous FGF18 expression than SPC212 but nevertheless strong overexpression of ectopically expressed FGF18 could be achieved in both cell lines compared with the parental cell lines as well as the respective vector controls (Figure 2a).

First, we assessed the impact of FGF18 on cell growth. While M38K<sup>FGF18</sup> showed no difference to the vector control, clonogenic growth was significantly reduced in SPC212<sup>FGF18</sup> compared with SPC212<sup>VC</sup> (Figure 2b). We also investigated cell migration, but again found no change in response to FGF18 overexpression in the M38K cell line. SPC212<sup>FGF18</sup>, in contrast, showed a significant increase in cell migration (Figure 2c). Together, these findings suggest that FGF18 may influence the behavior of a subset of PM cells.

### Circulating FGF18 levels in healthy controls and patients with PM or pleural fibrosis

Since FGF18 showed some impact on PM cell behavior and, moreover, patients with high FGF18 mRNA expression in the TCGA dataset tended to have a better OS, we next analyzed circulating FGF18 protein in the plasma of PM patients in order to assess its potential suitability as a biomarker. For that purpose, we performed ELISA assays of



**FIGURE 2** Overexpression of FGF18 results in decreased growth and enhanced migration in SPC212 but not in M38K cells. (a) FGF18 gene expression was determined in parental M38K and SPC212, corresponding vector controls (M38K<sup>VC</sup>, SPC212<sup>VC</sup>) and FGF18 overexpressing derivatives (M38K<sup>FGF18</sup>, SPC212<sup>FGF18</sup>) by qRT-PCR. The housekeeping gene GAPDH was used for normalization. (b) Cells were seeded at low density into six-well plates and colony formation was monitored for up to 14 days. Clonogenic growth was determined photometrically. Bars represent mean absorbance  $\pm$  SEM of  $n \geq 3$  repeats. (c) Cells were seeded into transwell chambers and transmigration to the lower side of the membrane was assessed photometrically after 48 h. Bars represent mean absorbance  $\pm$  SEM of  $n \geq 3$  repeats. \* $p < 0.05$ ; \*\* $p < 0.01$ ; ns, not significant; M38K<sup>FGF18</sup>/SPC212<sup>FGF18</sup> versus the respective vector controls; unpaired  $t$ -test.

plasma samples of 40 PM patients (median age 60.0 years, IQR: 52–69, 70% male) from two different institutions along with 40 healthy controls (median age 67.5 years, IQR: 62–72, 80% male) and 6 patients with benign pleural disease (median age 72, IQR: 61–76, 67% male).

First, the FGF18 levels were compared between patients with PM, patients with benign fibrosis and healthy individuals (Figure 3a). Surprisingly, the median FGF18 levels in PM patients were significantly lower ( $n = 40$ ; 112.3 pg/mL, IQR: 79.7–142.5) than in healthy controls ( $n = 40$ ; 192.4 pg/mL, IQR: 151.8–230.4;  $p < 0.001$ ). Moreover, the median FGF18 levels were significantly lower in patients with benign fibrosis ( $n = 6$ , 115.5 pg/mL, IQR: 99.4–142.4) than in healthy controls ( $p = 0.004$ ). No significant difference in FGF18 could be observed between patients with PM and




patients with fibrosis ( $p = 0.974$ ). Receiver operating characteristic (ROC) curve analysis was performed to assess the ability of FGF18 to discriminate between healthy individuals and patients with PM and showed an area under the curve of 0.837 (Figure 3b). When the six patients with fibrosis were included, the AUCs for discriminating between healthy controls and all patients (fibrosis plus PM) and between presence (PM patients) or absence (healthy controls and

fibrosis patients) of malignant disease were 0.84 and 0.79, respectively (Figure S3).

### Comparison of circulating FGF18 levels with histological subtype, stage of disease and asbestos exposure

Within the PM group, 26/40 (65%) patients were  $\geq 65$  years old and 28/40 (70%) were male patients. Epithelioid histology made up 80% ( $n = 32/40$ ) of all cases. Thirteen of 40 patients presented with early-stage disease (IMIG stage I and II), while 27/40 patients were diagnosed in an advanced stage (IMIG stage III and IV). Treatment strategies included radical surgery as part of multimodality treatment protocols (45%,  $n = 18$ ), chemo- and/or radiotherapy (50%,  $n = 20$ ) and best supportive care (5%,  $n = 2$ ). Based on the median FGF18 value, the study cohort was divided into patients with high and low FGF18 levels. Detailed baseline characteristics of both groups are displayed as Table 1. Between low and high FGF18 groups, no significant differences in age ( $p = 0.234$ ), sex ( $p = 0.490$ ), histology ( $p = 0.114$ ), stage ( $p = 0.567$ ), and treatment ( $p = 0.329$ ) were observed. However, there was a recognizable, not significant tendency toward higher median plasma FGF18 levels in the non-epithelioid group ( $n = 8/40$ ; 143.0 pg/mL; IQR: 88.2–191.5; the non-epithelioid group consisted of 5 patients with biphasic PM, 2 patients with sarcomatoid PM, and 1 patient with desmoplastic PM [Figure S4]) when compared with the group with epithelioid histology ( $n = 32/40$ , 109.4 pg/mL;




**FIGURE 3** FGF18 is significantly reduced in patients with pleural mesothelioma (PM) or pleural fibrosis compared with healthy controls. (a) FGF18 levels were determined by ELISA in patient plasma and values were compared between patients with malignant PM, patients with pleural fibrosis and healthy individuals (control). Values are shown as scatter dot plots, medians are shown as horizontal lines. \*\* $p < 0.01$ ; \*\*\* $p < 0.001$ ; ns, not significant; Kruskal–Wallis test. (b) Receiver operating characteristic (ROC) curve analysis showing the ability of FGF18 to discriminate between healthy individuals and patients with PM (AUC 0.84, 95% CI: 0.75–0.93,  $p < 0.0001$ ).

**TABLE 1** Clinicopathological characteristics of the PM patient cohort grouped by circulating FGF18.

Demographics	Study cohort ( $n = 40$ )	Low FGF18 ( $n = 20$ )	High FGF18 ( $n = 20$ )	$p$ -value
Age, years, median, IQR	60 (52–69)	59 (48–64)	64 (53–71)	0.234
Sex				0.490
Male	28 (70%)	15 (75%)	13 (65%)	
Female	12 (30%)	5 (25%)	7 (35%)	
Histology				0.114
Epithelioid	32 (80%)	18 (90%)	14 (70%)	
Non-epithelioid	8 (20%)	2 (10%)	6 (30%)	
Stage				0.567
I	2 (5%)	1 (5%)	1 (5%)	
II	11 (27.5%)	6 (30%)	5 (25%)	
III	15 (37.5%)	9 (45%)	6 (30%)	
IV	12 (30%)	4 (20%)	8 (40%)	
Treatment				0.329
Surgery-based MMT	18 (45%)	10 (50%)	8 (40%)	
Chemo- and/or radiotherapy	20 (50%)	10 (50%)	10 (50%)	
Best supportive care	2 (5%)	0 (0%)	2 (10%)	
Site				0.525
Left	18 (45%)	10 (50%)	8 (40%)	
Right	22 (55%)	10 (50%)	12 (60%)	

Abbreviations: IQR, interquartile range; MMT, multimodal treatment; PM, pleural mesothelioma.



**FIGURE 4** FGF18 is not significantly associated with histology, stage of disease or asbestos exposure. (a) FGF18 levels in the plasma were compared between patients with epithelioid and nonepithelioid pleural mesothelioma (PM). (b) FGF18 levels in the plasma were compared between patients with early-stage disease (IMIG stage I and II) and patients diagnosed in an advanced stage (IMIG stage III and IV). (c) FGF18 levels in the plasma were compared between patients with and without asbestos exposure. Values are shown as scatter dot plots, medians are shown as horizontal lines. ns, not significant; Mann–Whitney U test.


IQR: 79.7–133.2;  $p = 0.146$ ) (Figure 4a). There was no difference in plasma FGF18 levels between patients with early-stage disease and patients with advanced disease (Figure 4b) or between patients with ( $n = 25$ ) and without ( $n = 15$ ) anamnestically established asbestos exposure (Figure 4c).

### Correlation of circulating FGF18 levels with disease prognosis in PM

Finally, we tested whether levels of circulating FGF18 correlate with patient prognosis. Median OS for the entire cohort was 20.733 months (HR 3.612, 95% CI: 13.655–27.812). PM patients with low FGF18 levels had a longer, however not significantly longer overall survival when compared with those with high FGF18 levels (median survival 24.167 vs. 18.900 months, HR 0.821, 95% CI: 0.378–1.783,  $p = 0.618$ ) (Figure 5). We performed univariate and multivariate survival analyses including age, sex, histologic subtype, FGF18 levels, tumor site, tumor stage, and type of treatment (Table 2). Epithelioid histology held a prognostic value in univariate analysis (epithelioid vs. nonepithelioid; HR 2.905, 95% CI: 1.131–7.461,  $p = 0.027$ ). No independent predictors, however, were detected by multivariate analysis. FGF18 was not found to be an independent prognostic factor for OS (low vs. high; HR 0.820, 95% CI: 0.330–2.039,  $p = 0.632$ ).

### DISCUSSION

Growth factors and their receptors can have multiple functions in the development and progression of cancer. They are frequently overexpressed compared with normal tissues and, in addition to stimulating tumor cell proliferation, they



**FIGURE 5** Circulating FGF18 is not associated with overall survival of pleural mesothelioma (PM) patients. (a) Kaplan–Meier survival analysis was performed for all patients of the cohort ( $n = 40$ ) dichotomized by the median level of circulating FGF18 (112.3 pg/mL). (b) Kaplan–Meier survival analysis was performed for patients with epithelioid PM ( $n = 32$ ). (c) Kaplan–Meier survival analysis was performed for patients with nonepithelioid PM ( $n = 8$ ).

have been shown to influence migration and invasion, neoangiogenesis and immune cell functions.<sup>31</sup> This makes them potential candidates both as biomarkers and as therapeutic targets, especially since growth factor receptors are often kinases that can be blocked with specific kinase inhibitory drugs. In mesothelioma, several growth factors have been demonstrated to contribute to cancer progression, influence prognosis or predict the response to specific therapies. For instance, our group has previously demonstrated that activin A, a member of the TGF- $\beta$  family, drives PM

**TABLE 2** Univariate and multivariate survival analyses of the PM patient cohort.

Variables	<i>n</i> = 40	OS (CI)	Univariate <i>p</i> -value	HR	95% CI	Multivariate <i>p</i> -value
<b>Age</b>			0.602			0.678
<65	26	24.30 (17.05–31.55)		0.66	0.49–0.89	
>65	14	15.63 (5.48–25.79)		1.51	1.12–2.05	
<b>Sex</b>			0.453			0.403
Male	28	24.30 (18.98–29.62)		1.35	0.95–1.92	
Female	12	17.60 (13.76–21.45)		0.74	0.52–1.05	
<b>Histology</b>			0.027			0.086
Epithelioid	32	24.3 (18.29–30.32)		2.91	1.13–7.46	
Nonepithelioid	8	6.4 (0.00–14.07)		0.34	0.13–0.88	
<b>FGF18 levels</b>			0.618			0.632
High	20	18.90 (8.67–29.13)		0.83	0.38–1.78	
Low	20	24.17 (15.75–32.58)		1.22	0.56–2.65	
<b>Site</b>			0.452			0.904
Right	22	19.33 (12.65–26.02)		1.19	0.88–1.60	
Left	18	24.30 (12.69–35.94)		0.84	0.62–1.14	
<b>Stage</b>			0.132			0.389
Early	13	24.47		2.02	0.81–5.05	
Late	27	18.90 (12.91–24.89)		0.50	0.20–1.24	
<b>Treatment</b>			0.227			0.599
Surgery-based MMT	18	24.30 (18.27–30.33)		1		
CTX and/or RTX	20	12.90 (0.00–27.96)		2.19	1.56–3.06	
BSC	2	1.53 (n/a)		4.00	2.48–6.46	

Abbreviations: BSC, best supportive care; CI, confidence interval; CTX, chemotherapy; HR, hazard ratio; MMT, multimodal treatment; PM, pleural mesothelioma; OS, overall survival; RTX, radiotherapy.

growth<sup>32</sup> and high circulating levels were associated with larger tumor volume and conferred a significantly worse OS in patients with epithelioid PM.<sup>28</sup> TGF- $\beta$  itself was associated with shorter OS when detected in pleural effusions but not when detected in blood.<sup>33</sup> Among the growth factors of the FGF family, high FGF2 was found to have negative prognostic impact in PM both in blood and pleural effusions.<sup>9,12</sup> In one previous study in PM, FGF9 and FGF18 gene expression were connected to loss of BAP1, a key tumor suppressor in PM, which in turn was suggested to indicate an increased sensitivity to the FGFR inhibitor AZD4547.<sup>34</sup> Of the two cell lines with BAP1 loss in our cell line panel, one showed high and one low FGF18 expression. For our patient cohort, no BAP1 status was available. Altered FGF18 expression has been reported in a number of different cancer types and its presence has been connected to both pro- and anti-tumorigenic activities. Our group has previously described overexpression of FGF18 in melanoma cells compared with primary melanocytes<sup>35</sup> and demonstrated a role in tumor progression in colon cancer via autocrine stimulation of tumor cells and paracrine stimulation of colon-associated fibroblasts and endothelial cells.<sup>19</sup> Enhancement of tumor progression by FGF18 has also been shown in ovarian cancer and hepatocellular carcinoma.<sup>20,21</sup> In previous breast

cancer studies, FGF18 gene expression was included in a five gene prognostic signature for disease free survival<sup>36</sup> and FGF18 enhanced breast cancer cell migration, invasion and EMT.<sup>37,38</sup> In gastroesophageal adenocarcinoma,<sup>39</sup> in contrast, as well as in clear cell renal cell cancer,<sup>40</sup> high FGF18 expression was found to be correlated with longer patient survival. In the latter case, FGF18 overexpression was, in addition, shown to inhibit proliferation and invasion of tumor cells in vitro and in vivo. In PM, we have previously found overexpression of FGF18 in tissue specimens and cell lines when compared with normal pleura cells.<sup>6</sup> High gene expression of FGF18 was confirmed in the current study in PM cell lines compared with most cell lines from other malignancies and is in line with the TCGA gene expression comparison across multiple cancer types. Surprisingly, not only did this not result in increased circulating FGF18 levels in PM patients compared with healthy controls, but PM patients even exhibited significantly lower levels of FGF18 than healthy controls. A possible explanation for this seemingly contradictory finding could be that a high number of FGFRs on PM cells as reported by us<sup>6,8</sup> and others<sup>10,34</sup> might lead to a rapid internalization of receptor-bound FGF18 and result in a more efficient clearing of FGF18 from the circulation.



While FGF18 was able to discriminate between healthy individuals and patients with PM, the lack of a significant difference between PM patients and patients with pleural fibrosis may limit its usefulness for diagnostic purposes. Several blood-based diagnostic biomarkers including mesothelin, calretinin, osteopontin, fibulin-3 and high-mobility group box 1 (HMGB1) have been proposed for PM.<sup>2,3,41</sup> A recent meta-analysis of diagnostic biomarkers in PM concluded that mesothelin, despite being by far the most investigated diagnostic biomarker in PM with ROC curve analyses showing AUCs >0.8 across multiple studies in serum, plasma or pleural effusions, lacks the sensitivity to be used as standalone biomarker.<sup>41</sup> Marker panels such as mesothelin, thioredoxin (TRX) and fibulin-3 in serum or mesothelin, calretinin and megakaryocyte potentiating factor (MTF) in plasma could help to improve performance.<sup>41–43</sup> While plasma FGF18 clearly does not represent a standalone biomarker for FGF18 diagnosis, its decrease in patients with pleural disease is an interesting finding and suggests further evaluation in combination with additional markers.

With respect to tumor biology, the effects of FGF18 reported in the literature are tissue-type specific. Our results show that overexpression of FGF18 in PM cells with very low endogenous FGF18 can result in decreased clonogenicity. This aligns with data from renal cell cancer<sup>40</sup> but contrasts with our previous results in colon cancer, where a strong stimulation of cell growth was found.<sup>19</sup> The cell model that showed decreased growth also showed a moderate increase in cell migration, which would be in agreement with the “go or grow hypothesis,” although a previous report dismissed this hypothesis for unstimulated mesothelioma cells.<sup>44</sup> Whether the net effect of these activities of FGF18 in vitro would favor or impair tumor progression in vivo remains unclear at present. Predominance of a growth limiting effect of FGF18 would suggest that its observed overexpression in PM cells could be a passenger effect rather than a driving event of tumorigenesis in PM, but might explain the trend towards longer OS in patients with high FGF18 gene expression observed in the TCGA dataset. These gene expression data prompted us to further investigate FGF18 as a prognostic biomarker in the circulation of patients. The subsequent ELISA analysis, however, revealed no significant correlation of FGF18 with OS or other clinicopathological parameters, essentially invalidating FGF18 as a blood-based prognostic marker in PM. It must be emphasized, however, that some of our results, especially those concerning patients with fibrosis and nonepithelioid PM are based on small sample numbers, which is a limitation of the current study. The findings for FGF18 are in contrast to its putative receptor FGFR3, which correlated with shorter OS in PM when analyzed by IHC in tissue specimens.<sup>8</sup> Data from gastric cancer suggest that FGF18 can also enact strong protumorigenic functions via FGFR2.<sup>45</sup> In PM, FGFR2 upregulation was connected to loss of the tumor suppressor NF2,<sup>46</sup> which is inactivated in around 20% of PM patients.<sup>47</sup> Tissue expression of FGFR2 in PM, however, had no prognostic power.<sup>8</sup>

Overall, our data disprove circulating FGF18 as a prognostic biomarker in PM. The decrease of circulating FGF18 in pleural disease and the role of FGF18 in PM biology should be further evaluated.

## AUTHOR CONTRIBUTIONS

Conceptualization, B.H., M.A.H., M.G.; software, T.M.; investigation, B.M., K.Sc., T.K., C.W., L.R., Y.D., K.Si., A.R.; resources, W.B., B.G.K., K.H., B.D.; data curation, B.M.; writing—original draft preparation, B.M., T.M., M.A.H., M.G.; writing—review and editing, all authors; visualization, B.M., M.G.; supervision, V.L., B.H., M.J.; funding acquisition, B.D. and M.G. All authors have read and agreed to the published version of the manuscript.

## ACKNOWLEDGMENTS

We thank Barbara Dekan and Barbara Peter-Vörösmarty for technical assistance, R. Stahel (University of Zurich) for the SPC212 and SPC111 cell lines, A. Catania (University of Milano) for the I2 cell line, V.L. Kinnula (University of Helsinki) for the M38K cell line and K. Grankvist (University of Umea) for the P31 cell line. This work was supported by the City of Vienna Fund for Innovative Interdisciplinary Cancer Research (Project Nr 21132) and the Berndorf Private Foundation to M.G. and the Austrian Science Fund Projects FWF I3522, FWF I3977, and FWF I4677 to B.D.

## CONFLICT OF INTEREST STATEMENT

The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

## DATA AVAILABILITY STATEMENT

All data are contained in the article and its supplementary files.

## ORCID

Balazs Dome  <https://orcid.org/0000-0001-8799-8624>

Balazs Hegedus  <https://orcid.org/0000-0002-4341-4153>

Michael Grusch  <https://orcid.org/0000-0001-5486-9340>

## REFERENCES

1. Sinn K, Mosleh B, Hoda MA. Malignant pleural mesothelioma: recent developments. *Curr Opin Oncol*. 2021;33:80–6. <https://doi.org/10.1097/CCO.0000000000000697>
2. Johnen G, Gawrych K, Raiko I, Casjens S, Pesch B, Weber DG, et al. Calretinin as a blood-based biomarker for mesothelioma. *BMC Cancer*. 2017;17:386. <https://doi.org/10.1186/s12885-017-3375-5>
3. Hollevoet K, Reitsma JB, Creaney J, Grigoriu BD, Robinson BW, Scherpereel A, et al. Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis. *J Clin Oncol*. 2012;30:1541–9. <https://doi.org/10.1200/JCO.2011.39.6671>
4. Ornitz DM, Itoh N. New developments in the biology of fibroblast growth factors. *WIREs Mech Dis*. 2022;14:e1549. <https://doi.org/10.1002/wsbm.1549>
5. Chioni AM, Grose RP. Biological significance and targeting of the FGFR Axis in cancer. *Cancers (Basel)*. 2021;13:5681. <https://doi.org/10.3390/cancers13225681>

6. Schelch K, Hoda MA, Klikovits T, Munzker J, Ghanim B, Wagner C, et al. Fibroblast growth factor receptor inhibition is active against mesothelioma and synergizes with radio- and chemotherapy. *Am J Respir Crit Care Med*. 2014;190:763–2. <https://doi.org/10.1164/rccm.201404-0658OC>
7. Schelch K, Wagner C, Hager S, Pirker C, Siess K, Lang E, et al. FGF2 and EGF induce epithelial-mesenchymal transition in malignant pleural mesothelioma cells via a MAPKinase/MMP1 signal. *Carcinogenesis*. 2018;39:534–45. <https://doi.org/10.1093/carcin/bgy018>
8. Vlacic G, Hoda MA, Klikovits T, Sinn K, Gschwandtner E, Mohorcic K, et al. Expression of FGFR1-4 in malignant pleural mesothelioma tissue and corresponding cell lines and its relationship to patient survival and FGFR inhibitor sensitivity. *Cell*. 2019;8:1091. <https://doi.org/10.3390/cells8091091>
9. Kumar-Singh S, Weyler J, Martin MJ, Vermeulen PB, Van Marck E. Angiogenic cytokines in mesothelioma: a study of VEGF, FGF-1 and -2, and TGF beta expression. *J Pathol*. 1999;189:72–8. [https://doi.org/10.1002/\(SICI\)1096-9896\(199909\)189:1<72::AID-PATH401>3.0.CO;2-O](https://doi.org/10.1002/(SICI)1096-9896(199909)189:1<72::AID-PATH401>3.0.CO;2-O)
10. Marek LA, Hinz TK, von Massenhausen A, Olszewski KA, Kleczko EK, Boehm D, et al. Nonamplified FGFR1 is a growth driver in malignant pleural mesothelioma. *Mol Cancer Res*. 2014;12:1460–9. <https://doi.org/10.1158/1541-7786.MCR-14-0038>
11. Stapelberg M, Gellert N, Swettenham E, Tomasetti M, Witting PK, Procopio A, et al. Alpha-tocopheryl succinate inhibits malignant mesothelioma by disrupting the fibroblast growth factor autocrine loop: mechanism and the role of oxidative stress. *J Biol Chem*. 2005;280:25369–76. <https://doi.org/10.1074/jbc.M414498200>
12. Strizzi L, Vianale G, Catalano A, Muraro R, Mutti L, Procopio A. Basic fibroblast growth factor in mesothelioma pleural effusions: correlation with patient survival and angiogenesis. *Int J Oncol*. 2001;18:1093–8. <https://doi.org/10.3892/ijo.18.5.1093>
13. Zhang X, Ibrahim OA, Olsen SK, Umemori H, Mohammadi M, Ornitz DM. Receptor specificity of the fibroblast growth factor family. The complete mammalian FGF family. *J Biol Chem*. 2006;281:15694–700. <https://doi.org/10.1074/jbc.M601252200>
14. Hoshikawa M, Yonamine A, Konishi M, Itoh N. FGF-18 is a neuron-derived glial cell growth factor expressed in the rat brain during early postnatal development. *Brain Res Mol Brain Res*. 2002;105:60–6. [https://doi.org/10.1016/S0169-328X\(02\)00393-5](https://doi.org/10.1016/S0169-328X(02)00393-5)
15. Ohbayashi N, Shibayama M, Kurotaki Y, Imanishi M, Fujimori T, Itoh N, et al. FGF18 is required for normal cell proliferation and differentiation during osteogenesis and chondrogenesis. *Genes Dev*. 2002;16:870–9. <https://doi.org/10.1101/gad.965702>
16. Usui H, Shibayama M, Ohbayashi N, Konishi M, Takada S, Itoh N. Fgf18 is required for embryonic lung alveolar development. *Biochem Biophys Res Commun*. 2004;322:887–92. <https://doi.org/10.1016/j.bbrc.2004.07.198>
17. Gauglhofer C, Sagmeister S, Schrottmaier W, Fischer C, Rodgarkia-Dara C, Mohr T, et al. Up-regulation of the fibroblast growth factor 8 subfamily in human hepatocellular carcinoma for cell survival and neoangiogenesis. *Hepatology*. 2011;53:854–64. <https://doi.org/10.1002/hep.24099>
18. Shimokawa T, Furukawa Y, Sakai M, Li M, Miwa N, Lin YM, et al. Involvement of the FGF18 gene in colorectal carcinogenesis, as a novel downstream target of the beta-catenin/T-cell factor complex. *Cancer Res*. 2003;63:6116–20.
19. Sonvilla G, Allerstorfer S, Stattner S, Karner J, Klimpfinger M, Fischer H, et al. FGF18 in colorectal tumour cells: autocrine and paracrine effects. *Carcinogenesis*. 2008;29:15–24. <https://doi.org/10.1093/carcin/bgm202>
20. Wei W, Mok SC, Oliva E, Kim SH, Mohapatra G, Birrer MJ. FGF18 as a prognostic and therapeutic biomarker in ovarian cancer. *J Clin Invest*. 2013;123:4435–8. <https://doi.org/10.1172/JCI70625>
21. Guo P, Wang Y, Dai C, Tao C, Wu F, Xie X, et al. Ribosomal protein S15a promotes tumor angiogenesis via enhancing Wnt/beta-catenin-induced FGF18 expression in hepatocellular carcinoma. *Oncogene*. 2018;37:1220–36. <https://doi.org/10.1038/s41388-017-0017-y>
22. Hu MC, Qiu WR, Wang YP, Hill D, Ring BD, Scully S, et al. FGF-18, a novel member of the fibroblast growth factor family, stimulates hepatic and intestinal proliferation. *Mol Cell Biol*. 1998;18:6063–74. <https://doi.org/10.1128/MCB.18.10.6063>
23. Zhang J, Zhou Y, Huang T, Wu F, Pan Y, Dong Y, et al. FGF18, a prominent player in FGF signaling, promotes gastric tumorigenesis through autocrine manner and is negatively regulated by miR-590-5p. *Oncogene*. 2019;38:33–46. <https://doi.org/10.1038/s41388-018-0430-x>
24. Vathipadiekal V, Wang V, Wei W, Waldron L, Drapkin R, Gillette M, et al. Creation of a human secretome: a novel composite library of human secreted proteins: validation using ovarian cancer gene expression data and a virtual Secretome Array. *Clin Cancer Res*. 2015;21:4960–9. <https://doi.org/10.1158/1078-0432.CCR-14-3173>
25. Pirker C, Bilecz A, Grusch M, Mohr T, Heidenreich B, Laszlo V, et al. Telomerase reverse transcriptase promoter mutations identify a genomically defined and highly aggressive human pleural mesothelioma subgroup. *Clin Cancer Res*. 2020;26:3819–0. <https://doi.org/10.1158/1078-0432.CCR-19-3573>
26. Grusch M, Schelch K, Riedler R, Reichhart E, Differ C, Berger W, et al. Spatio-temporally precise activation of engineered receptor tyrosine kinases by light. *EMBO J*. 2014;33:1713–26. <https://doi.org/10.15252/emboj.201387695>
27. Nowak AK, Chansky K, Rice DC, Pass HI, Kindler HL, Shemanski L, et al. The IASLC mesothelioma staging project: proposals for revisions of the T descriptors in the forthcoming eighth edition of the TNM classification for pleural mesothelioma. *J Thorac Oncol*. 2016;11:2089–99. <https://doi.org/10.1016/j.jtho.2016.08.147>
28. Hoda MA, Dong Y, Rozsas A, Klikovits T, Laszlo V, Ghanim B, et al. Circulating activin a is a novel prognostic biomarker in malignant pleural mesothelioma—a multi-institutional study. *Eur J Cancer*. 2016;63:64–73. <https://doi.org/10.1016/j.ejca.2016.04.018>
29. Kirschner MB, Pulford E, Hoda MA, Rozsas A, Griggs K, Cheng YY, et al. Fibulin-3 levels in malignant pleural mesothelioma are associated with prognosis but not diagnosis. *Br J Cancer*. 2015;113:963–NaN. <https://doi.org/10.1038/bjc.2015.286>
30. Chandrashekar DS, Bashel B, Balasubramanya SAH, Creighton CJ, Ponce-Rodriguez I, Chakravarthy B, et al. UALCAN: a portal for facilitating tumor subgroup gene expression and survival analyses. *Neoplasia*. 2017;19:649–58. <https://doi.org/10.1016/j.neo.2017.05.002>
31. Witsch E, Sela M, Yarden Y. Roles for growth factors in cancer progression. *Physiology (Bethesda)*. 2010;25:85–101. <https://doi.org/10.1152/physiol.00045.2009>
32. Hoda MA, Munzker J, Ghanim B, Schelch K, Klikovits T, Laszlo V, et al. Suppression of activin a signals inhibits growth of malignant pleural mesothelioma cells. *Br J Cancer*. 2012;107:1978–86. <https://doi.org/10.1038/bjc.2012.519>
33. Stockhammer P, Ploenes T, Theegarten D, Schuler M, Maier S, Aigner C, et al. Detection of TGF-beta in pleural effusions for diagnosis and prognostic stratification of malignant pleural mesothelioma. *Lung Cancer*. 2020;139:124–32. <https://doi.org/10.1016/j.lungcan.2019.11.013>
34. Quispel-Janssen JM, Badhai J, Schunselaar L, Price S, Brammell J, Iorio F, et al. Comprehensive pharmacogenomic profiling of malignant pleural mesothelioma identifies a subgroup sensitive to FGFR inhibition. *Clin Cancer Res*. 2018;24:84–94. <https://doi.org/10.1158/1078-0432.CCR-17-1172>
35. Metzner T, Bedeir A, Held G, Peter-Vorosmarty B, Ghassemi S, Heinze C, et al. Fibroblast growth factor receptors as therapeutic targets in human melanoma: synergism with BRAF inhibition. *J Invest Dermatol*. 2011;131:2087–95. <https://doi.org/10.1038/jid.2011.177>
36. Mustacchi G, Sormani MP, Bruzzi P, Gennari A, Zancanati F, Bonifacio D, et al. Identification and validation of a new set of five genes for prediction of risk in early breast cancer. *Int J Mol Sci*. 2013;14:9686–702. <https://doi.org/10.3390/ijms14059686>
37. Song N, Zhong J, Hu Q, Gu T, Yang B, Zhang J, et al. FGF18 enhances migration and the epithelial-mesenchymal transition in breast cancer by regulating Akt/GSK3beta/beta-catenin signaling. *Cell Physiol Biochem*. 2018;49:1019–32. <https://doi.org/10.1159/000493286>

38. Yu Z, Lou L, Zhao Y. Fibroblast growth factor 18 promotes the growth, migration and invasion of MDAMB231 cells. *Oncol Rep.* 2018;40:704–14. <https://doi.org/10.3892/or.2018.6482>
39. Jomrich G, Hudec X, Harpain F, Winkler D, Timelthaler G, Mohr T, et al. Expression of FGF8, FGF18, and FGFR4 in gastroesophageal adenocarcinomas. *Cells.* 2019;8:1092. <https://doi.org/10.3390/cells8091092>
40. Yang C, Zhang Z, Ye F, Mou Z, Chen X, Ou Y, et al. FGF18 inhibits clear cell renal cell carcinoma proliferation and invasion via regulating epithelial-mesenchymal transition. *Front Oncol.* 2020;10:1685. <https://doi.org/10.3389/fonc.2020.01685>
41. Schillebeeckx E, van Meerbeeck JP, Lamote K. Clinical utility of diagnostic biomarkers in malignant pleural mesothelioma: a systematic review and meta-analysis. *Eur Respir Rev.* 2021;30:210057. <https://doi.org/10.1183/16000617.0057-2021>
42. Demir M, Kaya H, Taylan M, Ekin A, Yilmaz S, Teke F, et al. Evaluation of new biomarkers in the prediction of malignant mesothelioma in subjects with environmental Asbestos exposure. *Lung.* 2016;194:409–17. <https://doi.org/10.1007/s00408-016-9868-1>
43. Jimenez-Ramirez C, Casjens S, Juarez-Perez CA, Raiko I, Del Razo LM, Taeger D, et al. Mesothelin, calretinin, and megakaryocyte potentiating factor as biomarkers of malignant pleural mesothelioma. *Lung.* 2019;197:641–9. <https://doi.org/10.1007/s00408-019-00244-1>
44. Garay T, Juhasz E, Molnar E, Eisenbauer M, Czirok A, Dekan B, et al. Cell migration or cytokinesis and proliferation?—revisiting the "go or grow" hypothesis in cancer cells in vitro. *Exp Cell Res.* 2013;319:3094–103. <https://doi.org/10.1016/j.yexcr.2013.08.018>
45. Zhang J, Wong CC, Leung KT, Wu F, Zhou Y, Tong JHM, et al. FGF18-FGFR2 signaling triggers the activation of c-Jun-YAP1 axis to promote carcinogenesis in a subgroup of gastric cancer patients and indicates translational potential. *Oncogene.* 2020;39:6647–3. <https://doi.org/10.1038/s41388-020-01458-x>
46. Wahiduzzaman M, Karnan S, Ota A, Hanamura I, Murakami H, Inoko A, et al. Establishment and characterization of CRISPR/Cas9-mediated NF2<sup>-/-</sup> human mesothelial cell line: molecular insight into fibroblast growth factor receptor 2 in malignant pleural mesothelioma. *Cancer Sci.* 2019;110:180–93. <https://doi.org/10.1111/cas.13871>
47. Bueno R, Stawiski EW, Goldstein LD, Durinck S, De Rienzo A, Modrusan Z, et al. Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations. *Nat Genet.* 2016;48:407–16. <https://doi.org/10.1038/ng.3520>

## SUPPORTING INFORMATION

Additional supporting information can be found online in the Supporting Information section at the end of this article.

**How to cite this article:** Mosleh B, Schelch K, Mohr T, Klikovits T, Wagner C, Ratzinger L, et al. Circulating FGF18 is decreased in pleural mesothelioma but not correlated with disease prognosis. *Thorac Cancer.* 2023;14(22):2177–86. <https://doi.org/10.1111/1759-7714.15004>